NEW YORK, NY / ACCESSWIRE / February 27, 2018 / U.S. markets rose for the third consecutive session on Monday on the strength of technology shares. The Dow Jones Industrial Average spiked 1.58 percent to close at 25,709.27 while the S&P 500 Index jumped 1.18 percent to close at 2,779.60. The Nasdaq Composite Index increased 1.15 percent to close at 7,421.46. The Dow and the S&P 500 are now just down 3.4 percent and 3.25 percent, respectively, from their all-time high, while the Nasdaq is just 1.1 percent shy from its peak, according to WSJ Market Data Group.
RDI Initiates Coverage on:
Achillion Pharmaceuticals, Inc.
Achillion Pharmaceuticals' stock jumped 15.40% Monday, to close the day at $3.41. The stock recorded a trading volume of 645,142 shares, which was above its three months average volume of 2,522,998 shares. In the last year, Achillion Pharmaceuticals' shares have traded in a range of 2.58 - 5.66. The share price has gained 32.17% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.91 is below its 200-day moving average of $3.67. Shares of Achillion Pharmaceuticals have gained roughly 20.07 percent in the past month and are up 18.04 percent year-to-date.
Access RDI's Achillion Pharmaceuticals, Inc. Research Report at:
On Monday, shares of Novavax recorded a trading volume of 6,799,756 shares, which was below the three months average volume of 10,873,065 shares. The stock ended the day 0.86% higher at 2.35. The share price has gained 152.69% from its 52-week low with a 52-week trading range of 0.93 - 2.60. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $2.02 is greater than its 200-day moving average of $1.38. Shares of Novavax have gained roughly 12.44 percent in the past month and are up 89.52 percent year-to-date.
Access RDI's Novavax, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.